Valproic Acid and Its Effects on HIV Latent Reservoirs

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
HIV Infections
Interventions
DRUG

Valproic Acid

Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.

DRUG

HAART

As per standard of care.

Trial Locations (6)

V6Z 1Y6

BC St-Paul's Hospital/Immunodeficiency Clinic, Vancouver

K1H 8L6

Ottawa Health Research Institute/Immunodeficiency Clinic, Ottawa

H2L 4P9

Actuel Medical Clinic, Montreal

H2L 5B1

Quartier Latin Medical Clinic, Montreal

H2X 2P4

Montreal Chest Institute/Immunodeficiency Clinic, Montreal

G1V 4G2

CHUL Ste-Foy, Ste-Foy

All Listed Sponsors
collaborator

Canadian Foundation for AIDS Research (CANFAR)

OTHER

collaborator

CIHR Canadian HIV Trials Network

NETWORK

lead

Jean-Pierre Routy

OTHER

NCT00289952 - Valproic Acid and Its Effects on HIV Latent Reservoirs | Biotech Hunter | Biotech Hunter